Hemab Therapeutics

COAGNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.131 B

$45.61 +1.15%

Close of 6 Nov 2026

As of 6 Nov 2026, Hemab Therapeutics (COAG) has a market capitalization of $2.13B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

46,712,117

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#31VericelVCEL$2.65B
#32Recursion PharmaceuticalsRXRX$2.18B
#33Hemab TherapeuticsCOAG$2.13B
#34Biocryst PharmaceuticalsBCRX$1.95B
#35Replimune GroupREPL$1.90B

What if Hemab Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$604,487.14

Per share 13,253× higher

Bitcoin $1.53T

$32,707.75

Per share 717× higher

Apple $5.02T

$107,376.48

Per share 2,354× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Hemab Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.